Artelo Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.3M
- Price
- $0.7201
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.08%
- Volume
- 40.8K
About
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
Quick stats
Shares outstanding4.6M
Computed float2.8M
Float / shares60.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001621221
Websitehttps://www.artelobio.com
AI Summary
AI-generated1/18
standardbullishoperations update
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
Artelo Biosciences received a notice of allowance from the Japanese Patent Office for the intended commercial formulation of its lead asset ART27.13, extending patent protection through 2041.
This decision aligns with prior allowances in the United States and Europe, securing the IP estate across three major pharmaceutical markets for the peripherally selective dual cannabinoid agonist.
The drug is currently being evaluated in two Phase 2 trials: CAReS for cancer-related anorexia and DREAM for glaucoma, with interim data showing positive weight trends at higher doses.